Idea Brunch Interview with Edwin Dorsey

I was recently interviewed by Edwin Dorsey on Sunday's Idea Brunch! We talked about my background and why I do things the way I do. I try to explain my reasoning with examples whenever I can.

I had a lot of fun on this one and Edwin asked great questions to bring out the conversation.

Enjoy!

NoName Annual Performance 2019-2020

Another incredible year!  I'm up 94.9%, giving me a CAGR of 52.5% since I started investing 7 years ago.  

    

****update Feb 21, 2021****

I made a calculation mistake when first writing this post.  My real return is 94.9%, not 85.3% which means my CAGR is really 52.5%, not 51.4%.  See comment at end of post for explanation.

You can read more on my performance in past annual posts here.

DIY Investing Podcast

Recently I was interviewed by Trey Henninger on the DIY Investing Podcast.  You can listen to it here.  I had a lot of fun on this one and I am getting more comfortable.  We talked about my investing process, HEMA, DEWY, and a crazy story with CLSI.  

Examples

Today I'd like to run through some examples of my stock purchases.  I've already blogged about these so nothing new on that front, but this will give you an idea how I go about buying stocks over the long term and why I buy when I do.

Let me try to tell you how I buy and why I buy.  What I do with winners and losers.  

I have 3 winners and 3 losers to run through.  Yay charts!

HEMA Annual Meeting June 2017

This will be a summary of today's HemaCare (HEMA) annual meeting.  There was nothing earth shattering but it was still good.  Shareholder attendance was down 33% from last year, which is to say there were only two of us this time...

HEMA is still cheap

It's now been about 10 months since my initial post on Hemacare (HEMA) so let's take a look at where we stand.  The company went dark to transform their business outside the public eye from a money losing blood bank into a growing bio research cell product supply company.  I thought (and still think) their plan is to file again with the SEC once they fully transition and show a couple years of good results.  My original investment was based on two main points.

Hemacare's transformation

A better investor than I told me about this company.  Hemacare (HEMA) is a $3.5M market cap company that has transformed their business in the darkness, outside the view of Wall Street.  HEMA started life decades ago as a blood bank.  Realizing the limitations of that business, leadership started down a new path several years ago.  They have refocused the company and are experiencing strong growth in the bioresearch space.  They are valued as if they are dying and herein lies the opportunity.  The investment community does not know of their transformation...yet...